Contrast

Contact

Share

MyChart

Help

Do I Qualify for a Third Dose of the COVID-19 Vaccine?

The U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) for both the Pfizer and Moderna COVID-19 Vaccines to allow for the use of an additional dose in certain immunocompromised individuals. This is as a result of medical studies suggesting a reduced antibody response after the usual two-dose vaccine primary series.

The Centers for Disease Control (CDC) now recommends an additional dose for patients:

  • Receiving treatment for a blood cancer (for example, leukemia, lymphoma, myeloma, myelodysplastic syndrome)
  • Receiving treatment for a solid tumor with chemotherapy, hormonal therapy, immunotherapy, surgery and/or radiation therapy (currently or within one year of initial mRNA COVID-19 vaccine series)
  • Received a stem cell transplant within the last two years or requiring immune-suppressing medication
  • Received a solid organ transplant (such as a kidney or liver transplant) and are taking immune-suppressing medication
  • Moderate or severe primary immunodeficiency (such as DiGeorge or Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV disease

If you are taking (or were taking at the time of your initial mRNA COVID-19 vaccine series) high-dose corticosteroids (equal to at least 20 mg of prednisone daily) or other medications that suppress the immune system, you are also eligible for a third dose of the COVID-19 vaccine. The list of eligible medications include:

  • 6-mercaptopurine (Purinethol, Purixin)
  • Abatacept (Orencia)
  • Adalimumab (Humira)
  • Alemtuzumab (Lemtrada, Campath)
  • Anakinra (Kineret)
  • Azathioprine (Imuran, Azasan)
  • Baricitinib (Olumiant)
  • Belatacept (Nulojix)
  • Benlimumab (Benlysta)
  • Certolizumab (Cimzia)
  • Cladribine (Mavenclad)
  • Cyclosporine (Gengraf, Neoral, Sandimmune)
  • Etanercept (Enbrel, Erelzi)
  • Fingolimod (Gilenya)
  • Golimumab (Simponi)
  • Infliximab (Remicade, Inflectra, Renflexis, Avsola)
  • Methotrexate (Otrexup, Rasuvo, Rheumatrex, Trexall)
  • Mycophenolate motefil (Cellcept, Myfortic)
  • Obinutuzumab (Gazyva)
  • Ocrelizumab (Ocrevus)
  • Ofatumumab (Kesimpta)
  • Ozanimod (Zeposa)
  • Rituximab (Rituxan, Truxima, Ruxience, Riabni)
  • Siponimod (Mayzent)
  • Sirolimus (Rapamune)
  • Tacrolimus (Prograf, Envarsus XR)
  • Tofacitinib (Xeljanz, Xeljanz XR)
  • Upadacitinib (Rinvoq)

If you have one of the above conditions, you are eligible to receive an additional dose if:

  1. You received two doses of the Pfizer vaccine, at least 28 days have passed since your last dose, and you are at least 12 years old;
    OR
  2. You received two doses of the Moderna vaccine, at least 28 days have passed since your last dose, and you are at least 18 years old.

If possible, the additional dose should be the same type of vaccine that you initially received. For example, if you received two doses of the Moderna vaccine, you should try to schedule your additional dose at a site that is offering the Moderna vaccine on the day of your appointment.

You will be asked to identify and confirm that you have one or more of the qualifying conditions at the time of scheduling. If you have questions about whether you are immunocompromised, please speak to your treating clinician.

Learn more about how to schedule an appointment online.